A new colorectal cancer drug has shocked researchers with how effective it is against the highly dangerous disease after it virtually cured every member of a clinical trial.
Dostarlimab, a monoclonal antibody drug, smashed expectations in a recent trial run by Memorial Sloan Kettering Cancer Center in New York. The drug effectively ‘unmasks’ hiding cancer cells, which then allows the immune system to identify and destroy them.
A year after the trial’s completion, each of the 18 participants had their disease go into complete remission, with doctors unable to find signs of cancer in their body.
While the trial was small, it is considered game-changing, and sets up the drug as a potential cure for one of the most dangerous common cancers known.
